Sildenafil

Research · Sildenafil

Overview

Sildenafil is a pyrazolopyrimidinone-based small molecule that acts as a selective inhibitor of phosphodiesterase type 5 (PDE5). It was originally developed by Pfizer researchers and was the first PDE5 inhibitor to reach clinical use; it is approved for clinical use in several jurisdictions. Its structure mimics the purine ring of cyclic guanosine monophosphate (cGMP), allowing competitive occupancy of the PDE5 catalytic site. It is widely used as a reference inhibitor in cyclic nucleotide and nitric oxide signaling research across vascular and pulmonary models.

Mechanism of action

Competitively inhibits PDE5, the enzyme that hydrolyzes cGMP in vascular and visceral smooth muscle, platelets, and other tissues. By preventing cGMP degradation, sildenafil potentiates signaling downstream of nitric oxide and soluble guanylate cyclase, enhancing protein kinase G activity, reducing intracellular calcium, and producing smooth muscle relaxation and vasodilation. It requires upstream nitric oxide release to exert its effect. Sildenafil shows lower but measurable inhibition of PDE6 in retinal photoreceptors. It is metabolized primarily by hepatic CYP3A4, with a minor CYP2C9 contribution, to an N-desmethyl metabolite with roughly half the parent's PDE5 potency.

Key research findings

1. 01

   Early characterization studies (1996) established sildenafil as an orally active, cGMP-specific PDE5 inhibitor with selectivity over other phosphodiesterase families.

2. 02

   In vitro studies in human corpus cavernosum smooth muscle cells characterized concentration-dependent elevation of cGMP in the presence of nitric oxide donors.

3. 03

   Preclinical rodent studies characterize effects on pulmonary vascular resistance and vascular remodeling in hypoxia-induced pulmonary hypertension models.

4. 04

   Clinical pharmacokinetic studies document rapid absorption and a terminal half-life of approximately 3 to 5 hours, with exposure increased by CYP3A4 inhibitors.

Published references

• Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction

  Boolell M et al. — Int J Impot Res, 1996 · PMID: 8858389

• Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells

  Moreland RB et al. — Life Sci, 1998 · PMID: 9600334

The information above is derived from published preclinical and clinical research. It is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.